VSTM News & Analysis
2 articles
Market Mood
Verastem (VSTM) Target Price Reduced to $14 with 211% Upside
RBC Capital maintained its Outperform rating on Verastem Inc. (NASDAQ: VSTM) and reduced the target price from $15 to $14, suggesting an upside potential of over 211%. This decision aligns with the firm's broader earnings preview for the biotech sector, following a rally in June. Verastem recently reported positive preliminary results from its Phase 1/2 trial for VS-7375, targeting late-stage KRAS G12D-mutated tumors. This information is significant for investors as it highlights the company's potential amid a favorable sentiment in the biotech sector.
Read More: Verastem (VSTM) Target Price Reduced to $14 with 211% Upside
Verastem (VSTM) Stock Price Target Lowered to $18 by BTIG
BTIG has lowered the stock price target for Verastem (VSTM) to $18 due to a revenue miss. This adjustment reflects concerns regarding the company's financial performance and future projections. Changes in price targets can impact investor sentiment and market trading behavior. Verastem's response to this target change will be closely monitored by market stakeholders.
Read More: Verastem (VSTM) Stock Price Target Lowered to $18 by BTIG